Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Katherine M Krajewski, M.D.

Co-Author

This page shows the publications co-authored by Katherine Krajewski and Toni Choueiri.
Connection Strength

5.367
  1. RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. AJR Am J Roentgenol. 2015 Mar; 204(3):W282-8.
    View in: PubMed
    Score: 0.631
  2. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist. 2014 May; 19(5):507-14.
    View in: PubMed
    Score: 0.594
  3. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer. 2014 Mar 01; 120(5):711-21.
    View in: PubMed
    Score: 0.577
  4. Radiologic response (RR) by MRI in patients (pts) with muscle-invasive urothelial cancer (MIUC) undergoing neoadjuvant chemotherapy. J Clin Oncol. 2013 Feb 20; 31(6_suppl):283.
    View in: PubMed
    Score: 0.548
  5. Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. Eur J Cancer. 2012 Jul; 48(10):1495-502.
    View in: PubMed
    Score: 0.505
  6. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011 May; 59(5):856-62.
    View in: PubMed
    Score: 0.475
  7. Radiogenomics in renal cell carcinoma. Abdom Radiol (NY). 2019 06; 44(6):1990-1998.
    View in: PubMed
    Score: 0.212
  8. Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088.
    View in: PubMed
    Score: 0.197
  9. Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunol Res. 2018 04; 6(4):402-408.
    View in: PubMed
    Score: 0.193
  10. Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer. 2018 01 22; 6(1):5.
    View in: PubMed
    Score: 0.193
  11. Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res. 2016 Jan; 4(1):12-7.
    View in: PubMed
    Score: 0.166
  12. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. Eur J Cancer. 2015 Nov; 51(17):2580-6.
    View in: PubMed
    Score: 0.163
  13. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015 May; 67(5):952-8.
    View in: PubMed
    Score: 0.156
  14. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
    View in: PubMed
    Score: 0.149
  15. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer. 2012 Jul; 48(10):1519-24.
    View in: PubMed
    Score: 0.129
  16. Pneumonitis associated with mTOR therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings, and correlation with clinical outcome. J Clin Oncol. 2011 May 20; 29(15_suppl):e15176.
    View in: PubMed
    Score: 0.121
  17. Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. J Clin Oncol. 2011 May 20; 29(15_suppl):4570.
    View in: PubMed
    Score: 0.121
  18. Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. Eur J Med Genet. 2021 Oct 07; 104359.
    View in: PubMed
    Score: 0.062
  19. Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Mol Cancer Ther. 2020 02; 19(2):690-696.
    View in: PubMed
    Score: 0.054
  20. The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. Clin Genitourin Cancer. 2018 04; 16(2):e327-e333.
    View in: PubMed
    Score: 0.048
  21. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2016 05 15; 22(10):2445-2452.
    View in: PubMed
    Score: 0.042
  22. Everolimus- and temsirolimus-associated enteritis: report of three cases. J Clin Oncol. 2011 May 10; 29(14):e404-6.
    View in: PubMed
    Score: 0.030
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.